Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2.
Mol Cancer Ther. 2016.
PMID: 27256376
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, Damming D, Jacobs DC, Rouwette M, Egging DF, van den Dobbelsteen D, Beusker PH, Goedings P, Verheijden GF, Lemmens JM, Timmers M, Dokter WH.
van der Lee MM, et al. Among authors: beusker ph.
Mol Cancer Ther. 2015 Mar;14(3):692-703. doi: 10.1158/1535-7163.MCT-14-0881-T. Epub 2015 Jan 14.
Mol Cancer Ther. 2015.
PMID: 25589493
Item in Clipboard
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E, Groothuis P, Beusker P, Coumans R, Elgersma R, Menge W, Joosten J, Spijker H, Huijbregts T, de Groot V, Eppink M, de Roo G, Verheijden G, Timmers M.
Dokter W, et al.
Mol Cancer Ther. 2014 Nov;13(11):2618-29. doi: 10.1158/1535-7163.MCT-14-0040-T. Epub 2014 Sep 4.
Mol Cancer Ther. 2014.
PMID: 25189543
Item in Clipboard
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, Egging DF, Dokter WH, Verheijden GF, Lemmens JM, Timmers CM, Beusker PH.
Elgersma RC, et al. Among authors: beusker ph.
Mol Pharm. 2015 Jun 1;12(6):1813-35. doi: 10.1021/mp500781a. Epub 2015 Feb 18.
Mol Pharm. 2015.
PMID: 25635711
Item in Clipboard
A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.
Coumans RGE, Ariaans GJA, Spijker HJ, Renart Verkerk P, Beusker PH, Kokke BPA, Schouten J, Blomenröhr M, van der Lee MMC, Groothuis PG, Ubink R, Dokter WHA, Timmers CM.
Coumans RGE, et al. Among authors: beusker ph.
Bioconjug Chem. 2020 Sep 16;31(9):2136-2146. doi: 10.1021/acs.bioconjchem.0c00337. Epub 2020 Aug 25.
Bioconjug Chem. 2020.
PMID: 32697078
Item in Clipboard
"Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core.
de Groot FM, Albrecht C, Koekkoek R, Beusker PH, Scheeren HW.
de Groot FM, et al. Among authors: beusker ph.
Angew Chem Int Ed Engl. 2003 Sep 29;42(37):4490-4. doi: 10.1002/anie.200351942.
Angew Chem Int Ed Engl. 2003.
PMID: 14520746
No abstract available.
Item in Clipboard
Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L, de Groot FM, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A.
Devy L, et al. Among authors: beusker ph.
FASEB J. 2004 Mar;18(3):565-7. doi: 10.1096/fj.03-0462fje. Epub 2004 Jan 20.
FASEB J. 2004.
PMID: 14734647
Item in Clipboard
Rearrangement of O-cinnamoyltaxicin I to a novel C-13 spiro-taxane.
van Rozendaal EL, Veldhuis H, van Veldhuizen B, van Beek TA, de Groot A, Beusker PH, Scheeren HW.
van Rozendaal EL, et al. Among authors: beusker ph.
J Nat Prod. 2000 Feb;63(2):179-81. doi: 10.1021/np990206h.
J Nat Prod. 2000.
PMID: 10691703
Item in Clipboard
Cite
Cite